Methods for determining the risk of prenatal complications
View Patent ↗The disclosure relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual has for developing pre-eclampsia based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers. The disclosure also relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual is carrying a fetus having a chromosomal abnormality based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers.
1. A method for determining a risk of a chromosomal abnormality in a fetus, the method comprising:
determining the amount of placental growth factor (PlGF), pregnancy-associated plasma protein A (PAPP-A), and free human chorionic gonadotropin (free beta hCG) in one or more blood samples taken from a pregnant individual;
determining likelihood ratios of PlGF, PAPP-A, and free beta hCG for the individual; and
determining the risk of the chromosomal abnormality in the fetus using the likelihood ratios of PlGF, PAPP-A, and free beta hCG for the individual.
2. The method of claim 1 , wherein the chromosomal abnormality is selected from the group consisting of trisomy 21, trisomy 18, trisomy 13, Turner syndrome, and triploidy.
3. The method of claim 1 , the method further comprising determining one or more ultrasound markers of the fetus and determining the risk of the chromosomal abnormality in the fetus using the one or more ultrasound markers of the fetus and the likelihood ratios of PlGF, PAPP-A, and free beta hCG for the individual.
4. The method of claim 3 , wherein the ultrasound marker is nuchal translucency.
5. The method of claim 1 , the method further comprising determining the amount of at least one biochemical marker selected from placental protein 13 (PP13) and metalloprotease 12 (ADAM12) in the one or more blood samples taken from the pregnant individual and determining the risk of the chromosomal abnormality in the fetus using the amount of the at least one biochemical marker and the likelihood ratios of PlGF, PAPP-A, and free beta hCG for the individual.
6. The method of claim 1 , wherein the one or more blood samples are taken from the pregnant individual in the first trimester of pregnancy.
7. The method of claim 1 , wherein the one or more blood samples are taken from the pregnant individual within weeks 10 to 19 of pregnancy.
8. The method of claim 1 , wherein the one or more blood samples are taken from the pregnant individual within weeks 11 to 13 of pregnancy.
9. The method of claim 1 , wherein multivariate Gaussian analysis is performed to determine the likelihood ratios.
10. The method of claim 1 , the method further comprising:
determining a likelihood ratio for one or more maternal history parameters selected from the group consisting of race, smoking, parity, body mass index (BMI), hypertension, previous pre-eclampsia, and mother/sister with previous pre-eclampsia; and
determining the risk of the chromosomal abnormality in the fetus using the likelihood ratios of PlGF, PAPP-A, free beta hCG, and the one or more maternal history parameters.
11. The method of claim 1 , wherein determining the likelihood ratio for PlGF comprises determining a multiple of the median value for PlGF.
12. A medical profile for a pregnant individual, the medical profile comprising information for determining a risk of a chromosomal abnormality in a fetus, wherein the information comprises likelihood ratios of PlGF, PAPP-A, and free beta hCG in one or more blood samples from the pregnant individual, and wherein the medical profile is stored on a computer-readable medium.
13. The medical profile of claim 12 , wherein the medical profile further comprises additional information for determining the risk of developing pre-eclampsia, wherein the additional information comprises the blood pressure of the pregnant individual.
14. An apparatus for determining a risk of a chromosomal abnormality in a fetus, the apparatus comprising:
a data input means for inputting the amounts of PlGF, PAPP-A, and free beta hCG in one or more blood samples obtained from a pregnant individual;
a calculation means for determining likelihood ratios of PlGF, PAPP-A, and free beta hCG for the individual; and determining the risk of the chromosomal abnormality in the fetus using the likelihood ratios of PlGF, PAPP-A, and free beta hCG for the individual.
15. The apparatus of claim 14 , the apparatus further comprising:
a data input means for inputting at least one of the amounts of ADAM12 and PP13 in one or more blood samples obtained from the pregnant individual; and
a calculation means for determining the risk of the chromosomal abnormality in the fetus using the amounts of at least one of ADAM12 and PP13, and the likelihood ratios of PlGF, PAPP-A, and free beta hCG for the individual.
16. The apparatus of claim 14 , wherein the apparatus further determines a risk of developing pre-eclampsia, the apparatus further comprising:
a data input means for inputting a blood pressure of the pregnant individual; and
a calculation means for determining the risk of pre-eclampsia using the input amounts of one or more of PlGF and PAPP-A, and the blood pressure.